Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
暂无分享,去创建一个
F. Kronenberg | D. Marcelli | D. Wheeler | J. Floege | M. Froissart | T. Drueke | Iain A Gillespie | Á. D. de Francisco | Ioanna Gioni | I. A. Gillespie
[1] Florian Kronenberg,et al. Development and validation of a predictive mortality risk score from a European hemodialysis cohort , 2015, Kidney international.
[2] M. Burnier,et al. Drug adherence in chronic kidney diseases and dialysis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] C. Ghossein,et al. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[4] A. Rastogi,et al. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence , 2013, BMC Nephrology.
[5] K. Mahaffey,et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.
[6] D. Cukor,et al. Depression and nonadherence predict mortality in hemodialysis treated end‐stage renal disease patients , 2012, Hemodialysis international. International Symposium on Home Hemodialysis.
[7] M. Wolf,et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] H. Hemingway,et al. Current prescribing of statins and persistence to statins following ACS in the UK: a MINAP/GPRD study , 2012 .
[9] Florian Kronenberg,et al. An Epidemiological Study of Hemodialysis Patients Based on the European Fresenius Medical Care Hemodialysis Network: Results of the ARO Study , 2010, Nephron Clinical Practice.
[10] T. Browne,et al. Barriers to adult hemodialysis patients' self-management of oral medications. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] A. Macleod,et al. Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD) , 2009 .
[12] B. Hartmann,et al. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: A critical review of the literature , 2009, European journal of medical research.
[13] D. Goldsmith,et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] Supplemental Tables,et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.
[15] P. Kerr,et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] K. Rothman,et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[17] E. Bedrick,et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. , 2006, Kidney international.
[18] G. Eknoyan,et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.
[19] R. Foley,et al. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. , 2005, Journal of the American Society of Nephrology : JASN.
[20] B. Culleton,et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. , 2005, Journal of the American Society of Nephrology : JASN.
[21] F. Locatelli,et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.
[22] H Steil,et al. EuCliD® – A Medical Registry , 2004, Methods of Information in Medicine.
[23] S. Rosansky,et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.
[24] S. Moe,et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. , 2003, Kidney international.
[25] S. Ganesh,et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. , 2001, Journal of the American Society of Nephrology : JASN.
[26] F. Port,et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.